Roundtable Discussion: Evaluating the Need for Biomarker & Patient Selection Tools in an Increasingly Busy ADC Field

• What is the current need and appetite for ADC biomarker development and patient selection strategies?
• Discussing the different methodologies across machine learning and digital pathology to quantify IHC-derived ADC target expression
• Addressing the challenges and opportunities of biomarker analysis to select patient populations to benefit from specific ADCs
• Summarizing future predictions for precision medicine ADC development

Speakers:

Rakesh Dixit

Chief Executive Officer

Bionavigen